University of Pittsburgh | School of Medicine | Department of Pathology

SHERLOCK PROGRAM PODCAST

SEPTEMBER 2026

GUEST GUIDE

Meet the innovators joining the Sherlock Program Podcast this September.

Scan to visit the **SHERLOCK HUB** website!

REGISTRATION IS REQUIRED

For more information, please contact:

Dr. Christiano Alves
CRA92@pitt.edu

Jon Klosinski
jek176@pitt.edu

September 1, 2026 • 12:00 PM EST

SHERLOCK Speaker Series

Eric Green, M.D., Ph.D.

Co-Founder and Chief Executive Officer
Trace Neuroscience



Dr. Eric Green serves as Chief Executive Officer at Trace Neuroscience. He brings more than a decade of experience as a physician-scientist and entrepreneur building biotechnology companies that translate insights from human genetics into transformative medicines.

Throughout his career, Eric has launched and grown numerous leading biotechnology companies. As Co-Founder and Chief Scientific Officer at Maze Therapeutics, he built and led the scientific organization responsible for target discovery, validation, drug discovery, and translational science, with a strong emphasis on applying insights from human genetics. During his tenure, his team advanced five development candidates across multiple therapeutic modalities and disease areas.

Earlier in his career, Eric served as Head of Translational Research at MyoKardia, where he helped develop targeted therapies for serious cardiovascular diseases prior to the company's acquisition by Bristol Myers Squibb. He also co-founded iLab Solutions, a provider of web based software and services designed to streamline scientific research, which was later acquired by Agilent.

Eric is a board certified physician who completed his training in Internal Medicine and Cardiology at Brigham and Women's Hospital and serves as an adjunct faculty member at Stanford University. He earned an A.B. in History and Science from Harvard University and both his M.D. and Ph.D. in Chemical and Systems Biology from Stanford University.

September 8, 2026 • 12:00 PM EST

SHERLOCK Speaker Series



Luca Giani

Senior Principal, Investor & Serial Entrepreneur

Luca is a Senior Principal, investor, and serial entrepreneur with experience spanning venture creation, mergers and acquisitions, and translational science. He founded and served as CEO of Ilios Therapeutics, advancing a novel neuroscience platform targeting ALS, Parkinson's disease, and Alzheimer's disease. Under his leadership, the company built a diversified preclinical pipeline, advanced lead candidates, established foundational intellectual property, and positioned itself for strategic partnerships.

A Termeer Fellow and former Blavatnik Fellow in Life Science Entrepreneurship at Harvard Business School, Luca also served as a Technology and Public Purpose Fellow at Harvard's Belfer Center. Earlier in his career he co-founded Innbiotec Pharma and Somnifix, led investments at 5Lion Ventures, and worked in M&A at Credit Suisse and strategy consulting at Bain & Company. He holds a Master's with Distinction from Harvard and a B.S. magna cum laude from Georgetown University.



Shardule Shah, Ph.D.

CEO & Co-Founder, Lime Therapeutics

Dr. Shardule Shah is CEO and co-founder of Lime Therapeutics, where he is developing therapies for cancer and metabolic diseases including obesity. Between 2022 and 2025 he also served as a Termeer Fellow, Harvard Blavatnik Fellow for Life Sciences Entrepreneurship, and Harvard Business School Executive Fellow.

Prior to Lime, Dr. Shah held leadership roles at Lucira Health and Roche Molecular Diagnostics, managing global clinical operations and regulatory affairs for point of care diagnostic devices, including COVID-19 and influenza testing. He earned a Ph.D. in Immunology from Emory University, an MBA from Harvard Business School, an M.S. in Cell Biology from the University of Pennsylvania, and a B.S. in Biochemistry from Case Western Reserve University.

September 22, 2026 • 12:00 PM EST

SHERLOCK Speaker Series




Jihee Sohn, Ph.D.

Senior Principal Scientist, Clinical Biomarkers
Bristol Myers Squibb

Dr. Jihee Sohn is a Senior Principal Scientist specializing in Clinical Biomarkers at Bristol Myers Squibb, where she leads efforts supporting biomarker strategies for clinical development. Prior to joining Bristol Myers Squibb in 2025, she served as a Senior Scientist at Biogen and held research and faculty appointments at Harvard Medical School, Massachusetts General Hospital, and the University of Pittsburgh.

Dr. Sohn earned her Ph.D. in Cellular and Molecular Pathology from the University of Pittsburgh School of Medicine following a master's degree in Biochemistry and Molecular Biology from Georgetown University. Her work has advanced the fields of hematopoietic stem cell biology, immune regulation, and tissue engineering through both fundamental and translational research.



Cicera Lazzarotto, Ph.D.

Cell and Molecular Biologist

Dr. Cicera Lazzarotto is a cell and molecular biologist with extensive expertise in genome editing, genomic assay development, and genotoxicity profiling. Her research has focused on developing next-generation sequencing approaches to characterize gene editing outcomes and assess genome integrity, advancing the safe development of emerging genetic therapies.

In biotechnology, Dr. Lazzarotto has developed genomic assays, evaluated genome integrity, and supported regulatory submissions for genome editing technologies. She is also an experienced mentor who has guided junior scientists in experimental design, data analysis, and scientific communication, with a focus on advancing therapeutic innovation and improving patient outcomes.